0000000000664711

AUTHOR

Fiona Taylor

showing 2 related works from this author

Pooled analysis of who surgical safety checklist use and mortality after emergency laparotomy

2019

Background The World Health Organization (WHO) Surgical Safety Checklist has fostered safe practice for 10 years, yet its place in emergency surgery has not been assessed on a global scale. The aim of this study was to evaluate reported checklist use in emergency settings and examine the relationship with perioperative mortality in patients who had emergency laparotomy. Methods In two multinational cohort studies, adults undergoing emergency laparotomy were compared with those having elective gastrointestinal surgery. Relationships between reported checklist use and mortality were determined using multivariable logistic regression and bootstrapped simulation. Results Of 12 296 patients incl…

AdultMalebarriershumanoschecklist; surgery; human development indexGlobalSurg CollaborativeWHO Surgical Safety Checklist mortality emergency laparotomyWorld Health Organizationseguridad del pacienteNOCohort Studieslista de controlestudios prospectivosHumanstasa de supervivenciaProspective Studiesimplementationestudios de cohortesSurgery; implementation; health; barriersEmergency Treatment11 Medical and Health Sciencesmediana edadDigestive System Surgical ProceduresAgedancianoLaparotomyScience & TechnologyhealthOriginal ArticlesadultoMiddle Agedchecklist WHOprocedimientos quirúrgicos del sistema digestivoChecklistSurvival RateElective Surgical Procedureslaparotomíatratamiento de urgenciaSurgeryOriginal ArticleFemalePatient SafetyLife Sciences & Biomedicine
researchProduct

Checkmate 577:Health-related quality of life (HRQoL) in a randomized, double-blind phase III study of nivolumab (NIVO) versus placebo (PBO) as adjuva…

2021

167 Background: NIVO is the first adjuvant therapy to provide a statistically significant and clinically meaningful improvement in disease-free survival (DFS) versus PBO in resected EC/GEJC following neoadjuvant chemoradiotherapy as demonstrated by CheckMate 577. NIVO was well tolerated with an acceptable safety profile. This analysis provides additional information on the exploratory HRQoL endpoints in this clinical trial. Methods: The effect of NIVO versus PBO on HRQoL, including general and disease-related symptoms, functioning, disease burden, and overall QoL, was assessed using FACT-E and EQ-5D-3L patient-reported outcome (PRO) questionnaires administered at baseline (BL), every 4 wee…

Health related quality of lifeCancer Researchmedicine.medical_specialtybusiness.industrymedicine.medical_treatmentCancerGastroesophageal JunctionPlacebomedicine.diseaseGastroenterologyDouble blindOncologyInternal medicinemedicineAdjuvant therapyNivolumabbusinessAdjuvantJournal of Clinical Oncology
researchProduct